Trials / Completed
CompletedNCT04428424
Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients
The Impact of RF, and Anti-CCP on RA Patients in Response to Etanercept
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,493 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate available local data in Iraqi patients with rheumatoid arthritis on Enbrel treatment with regards to the impact of Rheumatoid factor and Anti-cyclic citrullinated peptide using data from the Baghdad Teaching Hospital registry.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enbrel | As provided in real world practice |
Timeline
- Start date
- 2020-07-05
- Primary completion
- 2020-08-30
- Completion
- 2020-08-30
- First posted
- 2020-06-11
- Last updated
- 2021-09-09
- Results posted
- 2021-09-09
Locations
1 site across 1 country: Iraq
Source: ClinicalTrials.gov record NCT04428424. Inclusion in this directory is not an endorsement.